Previous 10 | Next 10 |
Montrouge, France, April 19, 2023 D BV Technologies Outlin es Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specif...
Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions DBV Technologies (Euronext: DBV – ISIN: FR001...
2023-04-06 17:34:13 ET DBV Technologies ( NASDAQ: DBVT ) on Thursday filed for a mixed shelf offering of up to $250M. The offering may include ordinary shares, ordinary shares in the form of American depositary shares and warrants to purchase ordinary shares or Americ...
2023-04-03 08:55:13 ET Summary In December of 2022 I introduced a number of stocks which I was adding to my "Tax Loss Selling Basket". In this article I summarize the logic and criteria for the basket. I then tally up the results including calculating overall returns and looki...
Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock M...
Montrouge, France, March 13, 2023 DBV Technologies Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valle...
2023-03-08 16:05:11 ET A French %Biotech firm saw its shares rally strongly on Wednesday after the company announced that the first patient has been screened in the Company’s VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety Simplicity and Efficacy) Phase 3 clinical ...
Montrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screen ed in VITESSE Phase 3 Clinical Trial in Peanut - Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthma in Normal, Illino...
2023-03-06 08:32:34 ET BridgeBio Pharma ( BBIO ) +57% Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events. TCR2 Therapeutics ...
DBV Technologies S.A. (DBVT) Q4 2022 Results Conference Call March 02, 2023 05:00 PM ET Company Participants Anne Pollak - Head IR Daniel Tassé - CEO Sébastien Robitaille - CFO Pharis Mohideen - Chief Medical Officer Conference Call Participants ...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...